Xin Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xin Sun has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Zhouguang Hui
Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
4 shared publications Maoyuan Zhao
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
3 shared publicationsXu Yang
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
3 shared publicationsYu Men
Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
3 shared publicationsZeliang Ma
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
3 shared publicationsJingjing Kang
Department of Radiation Oncology Tongji University affiliated Shanghai Pulmonary Hospital Shanghai China
2 shared publications
Latest Publications
- 24 July 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 182, S664
MO-0794 Initial experience with DIBH radiotherapy for left breast cancer using SGRT and bore-based linac
- 24 July 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 182, S664
MO-0794 Initial experience with DIBH radiotherapy for left breast cancer using SGRT and bore-based linac
- Open Access
- 24 October 2022
- Published by Wiley in Thoracic Cancer
- Vol. 13 (23) , 3331-3340
Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer
Background: Combining antiangiogenic therapy with radioimmunotherapy is believed to further improve antitumor efficacy, but there is still a lack of evidence to support this. This study aimed to investigate the role of the tumor vascular‐targeted agent famitinib with a combination of radiotherapy and an immune checkpoint inhibitor in murine lung cancer.Methods: The effect of VEGFA and HIF1A on clinical prognosis and the tumor immune microenvironment was analyzed using public databases. Enrichment analyses of post‐irradiation gene expression and mRNAs related to immunotherapy efficacy were carried out based on GEO datasets. A C57BL/6 mouse subcutaneous tumor model was used to evaluate the antitumor effects of different treatment schemes. The tumor immunophenotyping was identified by flow cytometry.Results: We demonstrated that high level of VEGFA and HIF1A expression in lung cancer was related to poor prognosis and immunosuppressive tumor microenvironment. In a mouse model, the triple therapy of famitinib, radiotherapy and immunotherapy had the most dramatic antitumor activity. It significantly increased tumor infiltrating lymphocytes and reversed the immunosuppressive state of the tumor microenvironment in mice. Compared with radioimmunotherapy, the addition of famitinib further promoted the infiltration of CD8+ T cells and M1 type tumor associated macrophages, and reduced the number of myeloid suppressor cells. Therefore, triple therapy converted the immunosuppressive tumor microenvironment into an immunostimulatory one.Conclusion: Famitinib can synergize with radioimmunotherapy by regulating the tumor immune microenvironment in murine lung cancer.
- 24 October 2022
- Published by Wiley in Thoracic Cancer
- Vol. 13 (23) , 3331-3340
Open AccessFamitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer
Background: Combining antiangiogenic therapy with radioimmunotherapy is believed to further improve antitumor efficacy, but there is still a lack of evidence to support this. This study aimed to investigate the role of the tumor vascular‐targeted agent famitinib with a combination of radiotherapy and an immune checkpoint inhibitor in murine lung cancer.Methods: The effect of VEGFA and HIF1A on clinical prognosis and the tumor immune microenvironment was analyzed using public databases. Enrichment analyses of post‐irradiation gene expression and mRNAs related to immunotherapy efficacy were carried out based on GEO datasets. A C57BL/6 mouse subcutaneous tumor model was used to evaluate the antitumor effects of different treatment schemes. The tumor immunophenotyping was identified by flow cytometry.Results: We demonstrated that high level of VEGFA and HIF1A expression in lung cancer was related to poor prognosis and immunosuppressive tumor microenvironment. In a mouse model, the triple therapy of famitinib, radiotherapy and immunotherapy had the most dramatic antitumor activity. It significantly increased tumor infiltrating lymphocytes and reversed the immunosuppressive state of the tumor microenvironment in mice. Compared with radioimmunotherapy, the addition of famitinib further promoted the infiltration of CD8+ T cells and M1 type tumor associated macrophages, and reduced the number of myeloid suppressor cells. Therefore, triple therapy converted the immunosuppressive tumor microenvironment into an immunostimulatory one.Conclusion: Famitinib can synergize with radioimmunotherapy by regulating the tumor immune microenvironment in murine lung cancer.
- 12 February 2022
- Published by Wolters Kluwer Health in Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases
- Vol. 45 (2) , 191-194
[Bloody sputum with cavitary lesions on chest computed tomography scans: a case report].
This article reported a case of a middle-aged man with a 1-year history of intermittent cough and production of bloody sputum. Serum autoantibodies of the patient were negative. Early in the course of the disease, chest computed tomography (CT) scans showed a nodule in the right middle lung lobe with cavity formation. Surgical resection of the lesion was done with a postoperative pathological diagnosis of inflammatory pseudotumor. No treatment was given and his symptoms recurred with new patches in the right upper lobe. Pathology consultation from another hospital found vasculitis under the microscope and a diagnosis of granulomatosis with polyangiitis was made. His symptoms still worsened after glucocorticoid therapy. Final pathological consultation from Peking Union Medical College Hospital reached a diagnosis of pulmonary actinomycosis. Pulmonary lesions were absorbed after anti-infection treatment. The diagnosis and treatment of this patient provided more data for understanding of the relationship between infection and vasculitis among clinicians and pathologists.
- 12 February 2022
- Published by Wolters Kluwer Health in Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases
- Vol. 45 (2) , 191-194
[Bloody sputum with cavitary lesions on chest computed tomography scans: a case report].
This article reported a case of a middle-aged man with a 1-year history of intermittent cough and production of bloody sputum. Serum autoantibodies of the patient were negative. Early in the course of the disease, chest computed tomography (CT) scans showed a nodule in the right middle lung lobe with cavity formation. Surgical resection of the lesion was done with a postoperative pathological diagnosis of inflammatory pseudotumor. No treatment was given and his symptoms recurred with new patches in the right upper lobe. Pathology consultation from another hospital found vasculitis under the microscope and a diagnosis of granulomatosis with polyangiitis was made. His symptoms still worsened after glucocorticoid therapy. Final pathological consultation from Peking Union Medical College Hospital reached a diagnosis of pulmonary actinomycosis. Pulmonary lesions were absorbed after anti-infection treatment. The diagnosis and treatment of this patient provided more data for understanding of the relationship between infection and vasculitis among clinicians and pathologists.
- Open Access
- 14 December 2021
- Published by Wiley in Thoracic Cancer
- Vol. 13 (3) , 404-411
Postoperative radiotherapy improves survival of patients with ypN2 non‐small cell lung cancer after neoadjuvant chemotherapy followed by surgery – A propensity score matching study of the Surveillance, Epidemiology, and End Results database
Background: For patients with ypN2 non‐small cell lung cancer (NSCLC) after neoadjuvant chemotherapy followed by surgery (NCS), the role of postoperative radiotherapy (PORT) is unclear. The aim of our study was to evaluate the effect of PORT on survival of ypN2 NSCLC patients after NCS.Methods: Between 2004 and 2015, patients with ypN2 NSCLC after NCS were filtrated from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was used to balance the baseline characteristics of the PORT and non‐PORT groups. Kaplan–Meier method and Cox proportional hazards models were adopted to estimate overall survival (OS) and cancer‐specific survival (CSS).Results: A total of 257 patients who met the criteria were included in the study. After PSM, 115 patients remained in each group. The survival of patients in the PORT group was significantly better than those in the non‐PORT group. Median OS was 36 months vs. 26 months, and 5‐year OS rate was 40.5% vs. 21.0% (p = 0.002). The median CSS was 38 months vs. 27 months, and the 5‐year CSS rate was 43.7% vs. 22.1% (p < 0.001). Multivariable analysis showed that PORT was an independent prognostic factor for OS (HR = 0.59, 95% CI: 0.43–0.82, p = 0.001) and CSS (HR = 0.56, 95% CI: 0.41–0.78, p = 0.001). Subgroup analysis showed that patients in the following subgroups could benefit from PORT: age ≤ 70, diagnosed in the later period (2010–2015), white race, squamous cell carcinoma, grade III–IV, lobectomy, stage T3‐4, or with positive regional nodes ≤3 or > 3.Conclusions: For patients with ypN2 NSCLC after NCS, PORT significantly improves OS and CSS. These results need to be confirmed by further randomized studies.
- 14 December 2021
- Published by Wiley in Thoracic Cancer
- Vol. 13 (3) , 404-411
Open AccessPostoperative radiotherapy improves survival of patients with ypN2 non‐small cell lung cancer after neoadjuvant chemotherapy followed by surgery – A propensity score matching study of the Surveillance, Epidemiology, and End Results database
Background: For patients with ypN2 non‐small cell lung cancer (NSCLC) after neoadjuvant chemotherapy followed by surgery (NCS), the role of postoperative radiotherapy (PORT) is unclear. The aim of our study was to evaluate the effect of PORT on survival of ypN2 NSCLC patients after NCS.Methods: Between 2004 and 2015, patients with ypN2 NSCLC after NCS were filtrated from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was used to balance the baseline characteristics of the PORT and non‐PORT groups. Kaplan–Meier method and Cox proportional hazards models were adopted to estimate overall survival (OS) and cancer‐specific survival (CSS).Results: A total of 257 patients who met the criteria were included in the study. After PSM, 115 patients remained in each group. The survival of patients in the PORT group was significantly better than those in the non‐PORT group. Median OS was 36 months vs. 26 months, and 5‐year OS rate was 40.5% vs. 21.0% (p = 0.002). The median CSS was 38 months vs. 27 months, and the 5‐year CSS rate was 43.7% vs. 22.1% (p < 0.001). Multivariable analysis showed that PORT was an independent prognostic factor for OS (HR = 0.59, 95% CI: 0.43–0.82, p = 0.001) and CSS (HR = 0.56, 95% CI: 0.41–0.78, p = 0.001). Subgroup analysis showed that patients in the following subgroups could benefit from PORT: age ≤ 70, diagnosed in the later period (2010–2015), white race, squamous cell carcinoma, grade III–IV, lobectomy, stage T3‐4, or with positive regional nodes ≤3 or > 3.Conclusions: For patients with ypN2 NSCLC after NCS, PORT significantly improves OS and CSS. These results need to be confirmed by further randomized studies.
- Open Access
- 22 December 2020
- Published by Springer Nature in Research Square
The Risk of Cardiac-related Mortality in Stage IIIA-N2 Non-small Cell Lung Cancer: Analysis of the Surveillance, Epidemiology, and End Results Database
Background: We aimed to investigate the association between postoperative radiotherapy (PORT) and cardiac-related mortality for patients with ⅢA-N2 non-small cell lung cancer (NSCLC) by the Surveillance, Epidemiology, and End Results (SEER) database.Methods: The United States (US) population based SEER database were queried for cardiac-related mortality among patients with ⅢA-N2 NSCLC. Cardiac-related mortality was compared between PORT and Non-PORT group. Accounting for mortality from other causes, Gray’s test compared cumulative incidences of cardiac-related mortality between both groups. Univariate and multivariate analysis were performed using the competing risk model.Results: From 1988 to 2016, 7290 patients met the inclusion criteria: 3386 patients treated with PORT and 3904 patients treated with Non-PORT. The 5-year overall incidence of cardiac-related mortality was 3.01% in PORT group and 3.26% in Non-PORT group. Older age, male sex, squamous cell lung cancer, earlier year of diagnosis and earlier T stage were independent adverse factors for cardiac-related mortality. However, PORT use wasn’t associated with an increase in the hazard for cardiac-related mortality (subdistribution hazard ratio [SHR]=0.99, 95% confidence interval [95% CI], 0.78–1.24, p=0.91). When evaluating cardiac-related mortality in each time period, the overall incidence of cardiac-related mortality was decreased over time. There were no statistically significant differences based on PORT use in all time periods.Conclusions: With a median follow-up of 25 months, no significant differences were found in cardiac-related mortality between PORT and Non-PORT for ⅢA-N2 NSCLC patients.
- 22 December 2020
- Published by Springer Nature in Research Square
Open AccessThe Risk of Cardiac-related Mortality in Stage IIIA-N2 Non-small Cell Lung Cancer: Analysis of the Surveillance, Epidemiology, and End Results Database
Background: We aimed to investigate the association between postoperative radiotherapy (PORT) and cardiac-related mortality for patients with ⅢA-N2 non-small cell lung cancer (NSCLC) by the Surveillance, Epidemiology, and End Results (SEER) database.Methods: The United States (US) population based SEER database were queried for cardiac-related mortality among patients with ⅢA-N2 NSCLC. Cardiac-related mortality was compared between PORT and Non-PORT group. Accounting for mortality from other causes, Gray’s test compared cumulative incidences of cardiac-related mortality between both groups. Univariate and multivariate analysis were performed using the competing risk model.Results: From 1988 to 2016, 7290 patients met the inclusion criteria: 3386 patients treated with PORT and 3904 patients treated with Non-PORT. The 5-year overall incidence of cardiac-related mortality was 3.01% in PORT group and 3.26% in Non-PORT group. Older age, male sex, squamous cell lung cancer, earlier year of diagnosis and earlier T stage were independent adverse factors for cardiac-related mortality. However, PORT use wasn’t associated with an increase in the hazard for cardiac-related mortality (subdistribution hazard ratio [SHR]=0.99, 95% confidence interval [95% CI], 0.78–1.24, p=0.91). When evaluating cardiac-related mortality in each time period, the overall incidence of cardiac-related mortality was decreased over time. There were no statistically significant differences based on PORT use in all time periods.Conclusions: With a median follow-up of 25 months, no significant differences were found in cardiac-related mortality between PORT and Non-PORT for ⅢA-N2 NSCLC patients.
- 1 December 2019
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 108 (6) , 1701-1709
Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung Cancer
- 1 December 2019
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 108 (6) , 1701-1709
Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung Cancer